Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
Familial Cancer
Published in: Familial Cancer 4/2014

01-12-2014 | Original Article

Genetic 135G/C polymorphism of RAD51 gene and risk of cancer: a meta-analysis of 28,956 cases and 28,372 controls

Authors: Bei-bei Zhang, Dao-gang Wang, Chao Xuan, Gui-li Sun, Kai-feng Deng

Published in: Familial Cancer | Issue 4/2014

Login to get access

Abstract

The RAD51 gene is essential for the repair of damaged DNA related to tumor development. Although a number of genetic studies have attempted to link the 135G/C polymorphism of RAD51 gene to the risk of cancer, the results were inconclusive. The present study aimed at investigating the pooled association using the more comprehensive meta-analysis. The PubMed, EBSCO, and BIOSIS databases were searched to identify eligible studies which were published in English before March 2014. Data were extracted using standardized methods. The association was assessed by odds ratio (OR) with 95 % confidence interval (CI). Begg’s test was used to measure publication bias. Sensitivity analyses were also performed to assess the stability of the results. A total of 45 eligible studies with 28,956 patients and 28,372 controls were included in this meta-analysis. Overall, significant association was detected between 135G/C polymorphism and increased cancer risk (C allele vs. G allele: OR 1.23, 95 % CI 1.18–1.28; CC vs. GG: OR 2.41, 95 % CI 2.12–2.74; CC vs. CG: OR 3.86, 95 % CI 3.41–4.37; recessive model: OR 3.57, 95 % CI 3.19–4.00). In further stratified analysis, significantly elevated cancer risk was observed among Caucasians but not Asians. Subgroup analysis by different cancers also showed their significant associations in breast cancer, hematologic malignances, ovarian cancer, colorectal cancer and endometrial cancer, but not in head and neck cancer. Our results indicated that the RAD51 135G/C polymorphism was a candidate for susceptibility of cancer. The effect of the variants on the expression levels and the possible functional role of the variants in different cancers should be addressed in further studies.
Literature
1.
Pharoah PD, Dunning AM, Ponder BA, Easton DF (2004) Association studies for finding cancer-susceptibility genetic variants. Nat Rev Cancer 4(11):850–860PubMedCrossRef
2.
Cheng D, Shi H, Zhang K, Yi L, Zhen G (2014) RAD51 Gene 135G/C polymorphism and the risk of four types of common cancers: a meta-analysis. Diagn Pathol 9:18PubMedCentralPubMedCrossRef
3.
Bredberg A (2011) Cancer: more of polygenic disease and less of multiple mutations? A quantitative viewpoint. Cancer 117(3):440–445PubMedCrossRef
4.
Hoeijmakers JH (2001) Genome maintenance mechanisms for preventing cancer. Nature 411(6835):366–374PubMedCrossRef
5.
Krajinovic M, Labuda D, Mathonnet G et al (2002) Polymorphisms in genes encoding drugs and xenobiotic metabolizing enzymes, DNA repair enzymes, and response to treatment of childhood acute lymphoblastic leukemia. Clin Cancer Res Off J Am Assoc Cancer Res 8(3):802–810
6.
Finch SC (2007) Radiation-induced leukemia: lessons from history. Best Pract Res Clin Haematol 20(1):109–118PubMedCrossRef
7.
Alexander FE, Patheal SL, Biondi A et al (2001) Transplacental chemical exposure and risk of infant leukemia with MLL gene fusion. Cancer Res 61(6):2542–2546PubMed
8.
Shinohara A, Ogawa H, Matsuda Y, Ushio N, Ikeo K, Ogawa T (1993) Cloning of human, mouse and fission yeast recombination genes homologous to RAD51 and recA. Nat Genet 4(3):239–243PubMedCrossRef
9.
Zhao M, Chen P, Dong Y, Zhu X, Zhang X (2014) Relationship between Rad51 G135C and G172T variants and the susceptibility to cancer: a meta-analysis involving 54 case-control studies. PLoS ONE 9(1):e87259PubMedCentralPubMedCrossRef
10.
Vispe S, Defais M (1997) Mammalian Rad51 protein: a RecA homologue with pleiotropic functions. Biochimie 79(9–10):587–592PubMedCrossRef
11.
Baumann P, West SC (1998) Role of the human RAD51 protein in homologous recombination and double-stranded-break repair. Trends Biochem Sci 23(7):247–251PubMedCrossRef
12.
Thacker J (2005) The RAD51 gene family, genetic instability and cancer. Cancer Lett 219(2):125–135PubMedCrossRef
13.
14.
Hasselbach L, Haase S, Fischer D, Kolberg HC, Sturzbecher HW (2005) Characterisation of the promoter region of the human DNA-repair gene Rad51. Eur J Gynaecol Oncol 26(6):589–598PubMed
15.
Kawabata M, Kawabata T, Nishibori M (2005) Role of recA/RAD51 family proteins in mammals. Acta Med Okayama 59(1):1–9PubMed
16.
Gao LB, Pan XM, Li LJ et al (2011) RAD51 135G/C polymorphism and breast cancer risk: a meta-analysis from 21 studies. Breast Cancer Res Treat 125(3):827–835PubMedCrossRef
17.
Wang Z, Dong H, Fu Y, Ding H (2010) RAD51 135G > C polymorphism contributes to breast cancer susceptibility: a meta-analysis involving 26,444 subjects. Breast Cancer Res Treat 124(3):765–769PubMedCrossRef
18.
Yu KD, Yang C, Fan L, Chen AX, Shao ZM (2011) RAD51 135G > C does not modify breast cancer risk in non-BRCA1/2 mutation carriers: evidence from a meta-analysis of 12 studies. Breast Cancer Res Treat 126(2):365–371PubMedCrossRef
19.
Xuan C, Zhang BB, Yang T, Deng KF, Li M, Tian RJ (2012) Association between OCTN1/2 gene polymorphisms (1672C-T, 207G-C) and susceptibility of Crohn’s disease: a meta-analysis. Int J Colorectal Dis 27(1):11–19PubMedCrossRef
20.
Zhang BB, Xuan C, Deng KF, Wu N, Lun LM (2013) Association between the MDR1 gene variant C3435T and risk of leukaemia: a meta-analysis. Euro J Cancer Care 22(5):617–625CrossRef
21.
Xuan C, Lun LM, Zhao JX et al (2013) PTPN22 gene polymorphism (C1858T) is associated with susceptibility to type 1 diabetes: a meta-analysis of 19,495 cases and 25,341 controls. Ann Hum Genet 77(3):191–203PubMedCrossRef
22.
Kuschel B, Auranen A, McBride S et al (2002) Variants in DNA double-strand break repair genes and breast cancer susceptibility. Hum Mol Genet 11(12):1399–1407PubMedCrossRef
23.
Wang LE, Bondy ML, Shen H et al (2004) Polymorphisms of DNA repair genes and risk of glioma. Cancer Res 64(16):5560–5563PubMedCrossRef
24.
Seedhouse C, Faulkner R, Ashraf N, Das-Gupta E, Russell N (2004) Polymorphisms in genes involved in homologous recombination repair interact to increase the risk of developing acute myeloid leukemia. Clin Cancer Res Off J Am Assoc Cancer Res 10(8):2675–2680CrossRef
25.
Sliwinski T, Krupa R, Majsterek I et al (2005) Polymorphisms of the BRCA2 and RAD51 genes in breast cancer. Breast Cancer Res Treat 94(2):105–109PubMedCrossRef
26.
Webb PM, Hopper JL, Newman B et al (2005) Double-strand break repair gene polymorphisms and risk of breast or ovarian cancer. Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol 14(2):319–323CrossRef
27.
Lee KM, Choi JY, Kang C et al (2005) Genetic polymorphisms of selected DNA repair genes, estrogen and progesterone receptor status, and breast cancer risk. Clin Cancer Res Off J Am Assoc Cancer Res 11(12):4620–4626CrossRef
28.
Auranen A, Song H, Waterfall C et al (2005) Polymorphisms in DNA repair genes and epithelial ovarian cancer risk. Int J Cancer J Int du Cancer 117(4):611–618CrossRef
29.
Tarasov VA, Aslanyan MM, Tsyrendorzhiyeva ES, Litvinov SS, Gar’kavtseva RF, Altukhov YP (2006) Genetically determined subdivision of human populations with respect to the risk of breast cancer in women. Doklady biological sciences. In: proceedings of the Academy of Sciences of the USSR, Biological sciences sections/translated from Russian 406: 66–69
30.
Romanowicz-Makowska H, Smolarz B, Zadrozny M, Kulig A (2006) Analysis of RAD51 polymorphism and BRCA1 mutations in Polish women with breast cancer. Exp Oncol 28(2):156–159PubMed
31.
Poplawski T, Arabski M, Kozirowska D et al (2006) DNA damage and repair in gastric cancer—a correlation with the hOGG1 and RAD51 genes polymorphisms. Mutat Res 601(1–2):83–91PubMedCrossRef
32.
Rollinson S, Smith AG, Allan JM et al (2007) RAD51 homologous recombination repair gene haplotypes and risk of acute myeloid leukaemia. Leuk Res 31(2):169–174PubMedCrossRef
33.
Jakubowska A, Gronwald J, Menkiszak J et al (2007) The RAD51 135 G > C polymorphism modifies breast cancer and ovarian cancer risk in Polish BRCA1 mutation carriers. Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol 16(2):270–275CrossRef
34.
Lu J, Wang LE, Xiong P, Sturgis EM, Spitz MR, Wei Q (2007) 172G > T variant in the 5′ untranslated region of DNA repair gene RAD51 reduces risk of squamous cell carcinoma of the head and neck and interacts with a P53 codon 72 variant. Carcinogenesis 28(5):988–994PubMedCrossRef
35.
Jara L, Acevedo ML, Blanco R et al (2007) RAD51 135G > C polymorphism and risk of familial breast cancer in a South American population. Cancer Genet Cytogenet 178(1):65–69PubMedCrossRef
36.
Costa S, Pinto D, Pereira D et al (2007) DNA repair polymorphisms might contribute differentially on familial and sporadic breast cancer susceptibility: a study on a Portuguese population. Breast Cancer Res Treat 103(2):209–217PubMedCrossRef
37.
Antoniou AC, Sinilnikova OM, Simard J et al (2007) RAD51 135G → C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies. Am J Hum Genet 81(6):1186–1200PubMedCentralPubMedCrossRef
38.
Pharoah PD, Tyrer J, Dunning AM, Easton DF, Ponder BA (2007) Association between common variation in 120 candidate genes and breast cancer risk. PLoS Genet 3(3):e42PubMedCentralPubMedCrossRef
39.
Voso MT, Fabiani E, D’Alo F et al (2007) Increased risk of acute myeloid leukaemia due to polymorphisms in detoxification and DNA repair enzymes. Ann Oncol Off J Euro Soc Med Oncol ESMO 18(9):1523–1528CrossRef
40.
Figueroa JD, Malats N, Rothman N et al (2007) Evaluation of genetic variation in the double-strand break repair pathway and bladder cancer risk. Carcinogenesis 28(8):1788–1793PubMedCrossRef
41.
Synowiec E, Stefanska J, Morawiec Z, Blasiak J, Wozniak K (2008) Association between DNA damage, DNA repair genes variability and clinical characteristics in breast cancer patients. Mutat Res 648(1–2):65–72PubMedCrossRef
42.
Bhatla D, Gerbing RB, Alonzo TA et al (2008) DNA repair polymorphisms and outcome of chemotherapy for acute myelogenous leukemia: a report from the Children’s Oncology Group. Leukemia 22(2):265–272PubMedCentralPubMedCrossRef
43.
Werbrouck J, De Ruyck K, Duprez F et al (2008) Single-nucleotide polymorphisms in DNA double-strand break repair genes: association with head and neck cancer and interaction with tobacco use and alcohol consumption. Mutat Res 656(1–2):74–81PubMedCrossRef
44.
Jakubowska A, Jaworska K, Cybulski C et al (2009) Do BRCA1 modifiers also affect the risk of breast cancer in non-carriers? Eur J Cancer 45(5):837–842PubMedCrossRef
45.
Fabiani E, D’Alo F, Scardocci A et al (2009) Polymorphisms of detoxification and DNA repair enzymes in myelodyplastic syndromes. Leuk Res 33(8):1068–1071PubMedCrossRef
46.
Krupa R, Synowiec E, Pawlowska E et al (2009) Polymorphism of the homologous recombination repair genes RAD51 and XRCC3 in breast cancer. Exp Mol Pathol 87(1):32–35PubMedCrossRef
47.
Krupa R, Sobczuk A, Poplawski T, Wozniak K, Blasiak J (2011) DNA damage and repair in endometrial cancer in correlation with the hOGG1 and RAD51 genes polymorphism. Mol Biol Rep 38(2):1163–1170PubMedCentralPubMedCrossRef
48.
Jara L, Dubois K, Gaete D et al (2010) Variants in DNA double-strand break repair genes and risk of familial breast cancer in a South American population. Breast Cancer Res Treat 122(3):813–822PubMedCrossRef
49.
Romanowicz H, Smolarz B, Baszczynski J, Zadrozny M, Kulig A (2010) Genetics polymorphism in DNA repair genes by base excision repair pathway (XRCC1) and homologous recombination (XRCC2 and RAD51) and the risk of breast carcinoma in the Polish population. Pol J Pathol Off J Polish Soc Pathol 61(4):206–212
50.
Pasaje CF, Kim JH, Park BL et al (2011) Lack of association of RAD51 genetic variations with hepatitis B virus clearance and occurrence of hepatocellular carcinoma in a Korean population. J Med Virol 83(11):1892–1899PubMedCrossRef
51.
Dhillon VS, Yeoh E, Fenech M (2011) DNA repair gene polymorphisms and prostate cancer risk in South Australia–results of a pilot study. Urol Oncol 29(6):641–646PubMedCrossRef
52.
Hamdy MS, El-Haddad AM, Bahaa El-Din NM, Makhlouf MM, Abdel-Hamid SM (2011) RAD51 and XRCC3 gene polymorphisms and the risk of developing acute myeloid leukemia. J Invest Med Off Publ Am Fed Clin Res 59(7):1124–1130
53.
Liu L, Yang L, Mi Y et al (2011) RAD51 and XRCC3 polymorphisms: impact on the risk and treatment outcomes of de novo inv(16) or t(16;16)/CBFbeta-MYH11(+) acute myeloid leukemia. Leuk Res 35(8):1020–1026PubMedCrossRef
54.
Gil J, Ramsey D, Stembalska A et al (2012) The C/A polymorphism in intron 11 of the XPC gene plays a crucial role in the modulation of an individual’s susceptibility to sporadic colorectal cancer. Mol Biol Rep 39(1):527–534PubMedCrossRef
55.
Romanowicz-Makowska H, Smolarz B, Zadrozny M et al (2012) The association between polymorphisms of the RAD51-G135C, XRCC2-Arg188His and XRCC3-Thr241Met genes and clinico-pathologic features in breast cancer in Poland. Eur J Gynaecol Oncol 33(2):145–150PubMed
56.
Zhang L, Ruan Z, Hong Q et al (2012) Single nucleotide polymorphisms in DNA repair genes and risk of cervical cancer: a case-control study. Oncol Lett 3(2):351–362PubMedCentralPubMed
57.
Mucha B, Przybylowska-Sygut K, Dziki L, Dziki A, Sygut A, Majsterek I (2012) Lack of association between the 135G/C RAD51 gene polymorphism and the risk of colorectal cancer among Polish population. Polski przeglad chirurgiczny 84(7):358–362PubMedCrossRef
58.
Romanowicz-Makowska H, Smolarz B, Samulak D et al (2012) A single nucleotide polymorphism in the 5′ untranslated region of RAD51 and ovarian cancer risk in Polish women. Eur J Gynaecol Oncol 33(4):406–410PubMed
59.
Romanowicz-Makowska H, Samulak D, Michalska M et al (2012) RAD51 gene polymorphisms and sporadic colorectal cancer risk in Poland. Pol J Pathol Off J Pol Soc Pathol 63(3):193–198CrossRef
60.
Romanowicz-Makowska H, Smolarz B, Gajecka M et al (2012) Polymorphism of the DNA repair genes RAD51 and XRCC2 in smoking- and drinking-related laryngeal cancer in a Polish population. Arch Med Sci AMS 8(6):1065–1075CrossRef
61.
Gresner P, Gromadzinska J, Polanska K, Twardowska E, Jurewicz J, Wasowicz W (2012) Genetic variability of Xrcc3 and Rad51 modulates the risk of head and neck cancer. Gene 504(2):166–174PubMedCrossRef
62.
Romanowicz-Makowska H, Smolarz B, Polac I, Sporny S (2012) Single nucleotide polymorphisms of RAD51 G135C, XRCC2 Arg188His and XRCC3 Thr241Met homologous recombination repair genes and the risk of sporadic endometrial cancer in Polish women. J Obstet Gynaecol Res 38(6):918–924PubMedCrossRef
63.
Smolarz B, Zadrozny M, Duda-Szymanska J et al (2013) RAD51 genotype and triple-negative breast cancer (TNBC) risk in Polish women. Pol J Pathol Off J Pol Soc Pathol 64(1):39–43CrossRef
64.
Krivokuca AM, Malisic EJ, Dobricic JD, et al. (2013) RAD51 135G > C and TP53 Arg72Pro polymorphisms and susceptibility to breast cancer in Serbian women. Familial Cancer: Epub ahead of print
65.
Mohindra A, Hays LE, Phillips EN, Preston BD, Helleday T, Meuth M (2002) Defects in homologous recombination repair in mismatch-repair-deficient tumour cell lines. Hum Mol Genet 11(18):2189–2200PubMedCrossRef
66.
Dudas A, Chovanec M (2004) DNA double-strand break repair by homologous recombination. Mutat Res 566(2):131–167PubMedCrossRef
67.
68.
Yano K, Morotomi-Yano K, Adachi N, Akiyama H (2009) Molecular mechanism of protein assembly on DNA double-strand breaks in the non-homologous end-joining pathway. J Radiat Res 50(2):97–108PubMedCrossRef
69.
West SC (2003) Molecular views of recombination proteins and their control. Nat Rev Mol Cell Biol 4(6):435–445PubMedCrossRef
70.
O’Driscoll M, Jeggo PA (2006) The role of double-strand break repair—insights from human genetics. Nat Rev Genet 7(1):45–54PubMedCrossRef
71.
Khanna KK, Jackson SP (2001) DNA double-strand breaks: signaling, repair and the cancer connection. Nat Genet 27(3):247–254PubMedCrossRef
72.
Dixon K, Kopras E (2004) Genetic alterations and DNA repair in human carcinogenesis. Semin Cancer Biol 14(6):441–448PubMedCrossRef
73.
74.
Mendoza J, Martinez J, Hernandez C et al (2013) Association between ERCC1 and XPA expression and polymorphisms and the response to cisplatin in testicular germ cell tumours. Br J Cancer 109(1):68–75PubMedCentralPubMedCrossRef
75.
Zeljic K, Supic G, Jovic N et al (2014) Association of TLR2, TLR3, TLR4 and CD14 genes polymorphisms with oral cancer risk and survival. Oral Dis 20(4):416–424PubMedCrossRef
76.
He YZ, Hu X, Chi XS et al (2014) Association between RAD51 gene polymorphism (-135G/C) and susceptibility of myelodysplastic syndrome and acute leukemia: evidence based on a meta-analysis. Tumour Biol J Int Soc Oncodev Biol Med 35(1):615–621CrossRef
77.
Sun H, Bai J, Chen F et al (2011) RAD51 G135C polymorphism is associated with breast cancer susceptibility: a meta-analysis involving 22,399 subjects. Breast Cancer Res Treat 125(1):157–161PubMedCrossRef
78.
Wang W, Li JL, He XF et al (2013) Association between the RAD51 135 G > C polymorphism and risk of cancer: a meta-analysis of 19,068 cases and 22,630 controls. PLoS One 8(9):e75153PubMedCentralPubMedCrossRef
Metadata
Title
Genetic 135G/C polymorphism of RAD51 gene and risk of cancer: a meta-analysis of 28,956 cases and 28,372 controls
Authors
Bei-bei Zhang
Dao-gang Wang
Chao Xuan
Gui-li Sun
Kai-feng Deng
Publication date
01-12-2014
Publisher
Springer Netherlands
Published in
Familial Cancer / Issue 4/2014
Print ISSN: 1389-9600
Electronic ISSN: 1573-7292
DOI
https://doi.org/10.1007/s10689-014-9729-0

Other articles of this Issue 4/2014

Familial Cancer 4/2014 Go to the issue

Original Article

Association of interleukin-23 receptor gene polymorphisms with risk of bladder cancer in Chinese

Original Article

High-resolution melting (HRM) assay for the detection of recurrent BRCA1/BRCA2 germline mutations in Tunisian breast/ovarian cancer families

Short Communication

Association of reduced XRCC2 expression with lymph node metastasis in breast cancer tissues

Original Article

Distinct gene expression profiles in ovarian cancer linked to Lynch syndrome

Short Communication

Germline CDKN2A mutations in Brazilian patients of hereditary cutaneous melanoma

Original Article

Phenotype of SDHB mutation carriers in the Netherlands

2024 ASCO Annual Meeting Coverage

Highlights of the Day: Breast cancer – metastatic

Breast Cancer Video

In this session, Dr. Wolff provides his key takeaways from the data presented in the metastatic breast cancer oral abstract session at ASCO 2024.

Watch now

Highlights of the Day: Gynecologic cancer

Gynecologic Cancer Video

Highlights of the Day: Breast Cancer – local/regional/adjuvant

Breast Cancer Video

Neoadjuvant dual immunotherapy improves melanoma outcomes

04-06-2024 Melanoma News

» View more highlights on the ASCO 2024 congress hub page

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits